Phase II Trial Evaluating Efficacy of a Strategy Employing Combination Gemcitabine and Carboplatin Chemotherapy Followed by EBV [Epstein-Barr virus]-Specific Cytotoxic T-Lymphocytes in Patients With Metastatic or Locally Recurrent EBV-Positive Nasopharyngeal Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Carboplatin (Primary) ; Epstein-Barr virus-specific cytotoxic T lymphocytes (Primary) ; Gemcitabine (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 28 Jul 2008 Status changed from initiated to recruiting according to clinicaltrials.gov record.
- 02 Jul 2008 New trial record.